NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

Phase 1

Completed

• Conditions: Mild Cognitive Impairment
• Interventions: Other: Placebo; Drug: Niagen®

• Registration Number: NCT03482167
• Lead Sponsor: University of Delaware

Brief Summary

This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities. Overall, this project has the potential to identify a novel, safe and cost-effective strategy for decreasing age-related memory loss.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-02-14
• Study First Submitted QC: 2018-03-22
• Study First Posted: 2018-03-29
• Study Start: 2019-03-20
• Primary Completion: 2024-01-08
• Study Completion: 2024-01-22
• Results First Submitted: 2025-01-08
• Status Verified: 2025-04
• Results First Submitted QC: 2025-04-02
• Last Update Submitted: 2025-04-02
• Results First Posted: 2025-04-04
• Last Update Posted: 2025-04-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	placebo
Nicotinamide Riboside	Niagen®	Niagen® (ChromaDex, Inc.) 500 mg, twice daily

Primary Outcome Measures

Name	Time	Method
Cognitive Scores at Baseline and Week 12	baseline and 12 weeks	Primary outcome was a change from baseline in any domain of cognitive function. For all outcomes, a higher score indicates better cognitive function: 1. California Verbal Learning Test III (CVLT-III) Index Scores. Ability learn and recall a list of words over 5 trials and again after a 20 minute delay. Each Index Score has a mean of 100 and a standard deviation of 15 based on normative dataset (Range = 55 - 145).; 2. Wechsler Memory Scale IV (WMS-IV) Raw Scores.; * Logical Memory I \& II: Range = 0-50; * Logical Memory II Recognition: Range = 0-30; * Visual Reproduction I \& II: Range = 0-43; * Visual Reproduction II Recognition Score: Range = 0-7; 3. NIH Toolbox Fluid Composite Score. Composite Score has a mean of 100 and a standard deviation of 15 based on normative dataset (Range = 55 - 145) - based on several tests of fluid and crystallized cognition (episodic memory, attention, working memory, processing speed, executive function and language abilities).

Secondary Outcome Measures

Name	Time	Method
Cerebrovascular Reactivity at Baseline and 12 Weeks	baseline and 12 weeks	Relative (percent) change in blood velocity of the middle cerebral artery (MCA) per mmHg change in end-tidal carbon dioxide (ETCO2) during a brief period of hypercapnia.; Hypercapnia was induced by prospective end-tidal targeting (RespirAct, Thornhill Medical) in which a target change in end-tidal CO2 of +9mmHg was set. Data were only analyzed if ETCO2 changed by at least 6mmHg. All data were then normalized to the absolute change in ETCO2.
Total Brain Blood Flow at Baseline and 12 Weeks	baseline and 12 weeks	Total brain blood flow assessed by pseudo-continuous arterial spin labeling (pcASL). Total brain blood flow is measured in milliliters of blood per minute per 100 grams of brain tissue.
Aortic Stiffness at Baseline and 12 Weeks	baseline and 12 weeks	Carotid-femoral pulse wave velocity (CFPWV)
Blood Pressure at Baseline and 12 Weeks	baseline and 12 weeks	Seated systolic and diastolic blood pressure assessed using automated oscillometric sphygmomanometer.

Trial Locations

Locations (1)

Neurovascular Aging Laboratory; 🇺🇸 Newark, Delaware, United States